16 Jul 2026 04:51:43 ET │ 11 pages Ascletis Pharma (1672.HK) ASC30 global Phase III Cleared to Start; Broader pipeline strengthen BD optionality CITI'S TAKE On July 16th, we hosted a business update call with Ascletis founder & Chairman Dr. Jinzi Wu. ASC30's global Phase III has been cleared by FDA, with initiation now set for September 2026, and completion targeted July 2028, positioning it as a potential second-to-market oral small molecule GLP-1 globally. The company is simultaneously developing ASC48, t ...